Applied Therapeutics, Inc.
545 Fifth Avenue
Suite 1400
New York, NY 10017
United States
212 220 9226
https://www.appliedtherapeutics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 25
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Shoshana Shendelman Ph.D. | Chair of the Board of Directors, Founder, President, CEO & Secretary | 946.08k | 無 | 1979 |
| Mr. Les D. Funtleyder | CFO, Principal Financial Officer & Independent Director | 48.75k | 無 | 1971 |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer | 860.76k | 無 | 1961 |
| Mr. Constantine Chinoporos | COO & Chief Business Officer | 無 | 無 | 1966 |
| Ms. Catherine Thorpe | Chief Accounting Officer | 無 | 無 | 1964 |
| Mr. Corwin Dale Hooks | Chief Commercial Officer | 無 | 無 | 1967 |
描述
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
公司管治
截至 2024年5月1日 止，Applied Therapeutics, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：9；董事會：9；股東權利：7；現金賠償：10。
